Salvage therapy with bronchoscopic amphotericin B instillation plus systemic antifungals for refractory invasive pulmonary fungal infections in hematological patients

Background and purpose Refractory invasive pulmonary fungal infection (RIPFI) carries high mortality in hematological patients after first-line treatment failure. We evaluated the clinical response and safety of salvage therapy with bronchoscopic amphotericin B instillation (BABI) plus systemic antifungals in a retrospective cohort. Methods We retrospectively analyzed hematological patients with RIPFI receiving salvage therapy from 2019 to 2024. Clinical response was defined as complete/partial response (EORTC/MSG criteria). Univariable regression analysis was performed to explore factors potentially associated with treatment response. Results During a limited median follow-up of 67 days (IQR 49–76) covering all 97 patients, no deaths or serious adverse events occurred. After this period, 43 patients were transferred back to referring hospitals and were lost to further follow-up, while 54 patients continued follow-up at our center. Adverse events were infrequent (drug‑related: 16.5%; procedure‑related: 14.4%), mild, and resolved without treatment interruption. Patients received a median of 1 BABI procedure (IQR 1–3) in addition to systemic antifungal therapy. A clinical response was observed in 56.7% of patients (55 of 97). Univariable analysis suggested that several factors were associated with treatment response. Conclusions In this retrospective cohort, BABI plus systemic antifungals demonstrated acceptable safety and tolerability in selected hematological patients with RIPFI during limited follow‑up. Exploratory clinical response data are also presented, but causality cannot be established due to the lack of a control group. These exploratory findings require confirmation in prospective, controlled studies.

Authors

Institutions

Publication Details

Journal
BMC Infectious Diseases
Published
2026-11-19
DOI
https://doi.org/10.1186/s12879-026-14759-5
Primary Topic
Antifungal resistance and susceptibility
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Salvage therapy with bronchoscopic amphotericin B instillation plus systemic antifungals for refractory invasive pulmonary fungal infections in hematological patients

Nansheng Wan, Shuangyu Han, Mo Chen, Lei Yang et al.
BMC Infectious Diseases
Antifungal resistance and susceptibility
article

Salvage therapy with bronchoscopic amphotericin B instillation plus systemic antifungals for refractory invasive pulmonary fungal infections in hematological patients

Nansheng Wan, Shuangyu Han, Mo Chen, Lei Yang, Jing Feng, Yubao Wang, Guangsheng Li, Mengyuan Gao, Jie Wang
article en

Abstract

Background and purpose Refractory invasive pulmonary fungal infection (RIPFI) carries high mortality in hematological patients after first-line treatment failure. We evaluated the clinical response and safety of salvage therapy with bronchoscopic amphotericin B instillation (BABI) plus systemic antifungals in a retrospective cohort. Methods We retrospectively analyzed hematological patients with RIPFI receiving salvage therapy from 2019 to 2024. Clinical response was defined as complete/partial response (EORTC/MSG criteria). Univariable regression analysis was performed to explore factors potentially associated with treatment response. Results During a limited median follow-up of 67 days (IQR 49–76) covering all 97 patients, no deaths or serious adverse events occurred. After this period, 43 patients were transferred back to referring hospitals and were lost to further follow-up, while 54 patients continued follow-up at our center. Adverse events were infrequent (drug‑related: 16.5%; procedure‑related: 14.4%), mild, and resolved without treatment interruption. Patients received a median of 1 BABI procedure (IQR 1–3) in addition to systemic antifungal therapy. A clinical response was observed in 56.7% of patients (55 of 97). Univariable analysis suggested that several factors were associated with treatment response. Conclusions In this retrospective cohort, BABI plus systemic antifungals demonstrated acceptable safety and tolerability in selected hematological patients with RIPFI during limited follow‑up. Exploratory clinical response data are also presented, but causality cannot be established due to the lack of a control group. These exploratory findings require confirmation in prospective, controlled studies.

BMC Infectious Diseases
Tianjin Medical University General Hospital (CN), Tianjin Medical University (CN)
Antifungal resistance and susceptibility
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon